Cytiva broadens Xcellerex X-platform to include 500L and 2 000L bioreactors

March 25, 2025

• X-platform bioreactors are designed to help navigate challenges by combining reliability, scalability, and flexibility in one solution
• Scientists and researchers can seamlessly scale from 50L to 2 000L to meet growing demand for clinical trials and regulatory approved products

As researchers and scientists work to discover the next generation of advanced therapeutics, Cytiva is expanding the Xcellerex X-platform portfolio to meet their growing needs with the addition of 500L and 2 000L bioreactors. The X-platform is a reliable and flexible single-use system designed to increase operational efficiencies and production capacity, while helping to lower costs, reduce risks, and bring life-changing therapeutics to the next clinical milestone faster.

Ludovic Brellier, President of Hardware Solutions, Cytiva, says: “Our customers need speed and flexibility to develop advanced therapeutics. The expansion of Cytiva’s Xcellerex X-platform portfolio and its additional features will help our customers scale their operations more efficiently. The design and functionality of the hardware, biocontainers and software will allow our customers to safely manufacture life changing therapeutics faster.”

Why the X-Platform is different

The X-platform bioreactor portfolio was designed to meet the process needs of early-stage clinical researchers all the way through to commercial manufacturing. Customers can easily scale from 50L to 2 000L and while also reducing the time spent optimizing. Additional features include:

• An infrared-based camera that provides accurate detection of foam appearing in the process, allowing for early, automated intervention.
• Working height management of exhaust filters and heaters designed to simplify filter changes and minimize the need for manipulations at height.
• Quick and easy “off-the shelf” bag configuration and installation which helps reduce the risk of error. A rigid base construction ensures consistent installation of the single-use bioreactor bag, minimizing the risk of batch failure

History of Xcellerex

Xcellerex single-use technologies were launched more than 20 years ago and have played a significant role in the development of protein-based therapeutics, such as monoclonal antibodies (mAbs). The technology is now playing a critical role in the development of advanced therapeutics, such as cell and gene therapies, mRNA vaccines, and antibody drug conjugates.

See for yourself

The 2 000L X-platform bioreactor will be on display at Booth 2815 at InterPhex, in New York City, from April 1-3, 2025. Customers can contact their Cytiva representative to schedule demonstrations or place orders.

Learn more about Cytiva’s Xcellerex X-platform portfolio here.

Xcellerex is a trademark of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com

Media contact:

Colleen Connolly
[email protected]